Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | CHIEF DEVELOPMENT OFFICER | September 10, 2019 | March 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mirum Pharmaceuticals, Inc.
Report date September 10, 2019 · Filed March 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,369 |
Ending reported balance
After 2023-01-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-09-10 · Purchase · Acquired 965 · Balance 105,372 F1: The weighted average purchase price for the transaction reported was $10.64, and the range of prices were between $10.20 and $10.8799. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Row 2 · 2023-01-09 · Sale · Disposed 1,003 · Balance 104,369 F2: Shares sold to cover tax witholding obligations associated with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The weighted average purchase price for the transaction reported was $10.64, and the range of prices were between $10.20 and $10.8799. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F2: Shares sold to cover tax witholding obligations associated with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2024 Filed Feb 6, 2024 02:10 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 847 | $26.19 | $22,184.45 |
DisclosureSEC source: 0001415889-24-002756 · form4-02062024_020236.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,407 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:10 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001825 · form4-01252024_070106.xml · derivative · entry 2 Longpre Lara · CIK 0001780347 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:10 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001415889-24-001825 · form4-01252024_070106.xml · derivative · entry 1 Longpre Lara · CIK 0001780347 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-01-22 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 01:25 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,019 | $28.04 | $28,567.67 |
DisclosureSEC source: 0001415889-24-000883 · form4-01102024_010122.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,254 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| November 10, 2023 Filed Nov 16, 2023 01:13 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 434 | $22.29 | $9,672.56 |
DisclosureSEC source: 0001209191-23-055434 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,273 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 434 shares by the Reporting Person on November 10, 2023 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 23:37 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,004 | $25.65 | $25,749.19 |
DisclosureSEC source: 0001209191-23-041338 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,839 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| May 10, 2023 Filed May 19, 2023 20:05 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 684 | $16.92 | $11,575.67 |
DisclosureSEC source: 0001209191-23-030966 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,843 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 684 shares by the Reporting Person on May 10, 2023 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:46 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 38,500 | $0.00 Strike: $23.48 | $0.00 |
DisclosureSEC source: 0001209191-23-006312 · doc4.xml · derivative · entry 2 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,500 Underlying: Common Stock · 38,500 shares Expires 2033-01-30 F2 · derivative.exercise_date: 1/4th of the shares vest one year after January 31, 2023 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:46 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 9,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006312 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,159 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan. Read SEC document |
| January 09, 2023 Filed Mar 18, 2024 21:40 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,003 | $20.62 | $20,684.17 |
DisclosureSEC source: 0001415889-24-008316 · form4-03182024_090300.xml · nonDerivative · entry 2 Longpre Lara · CIK 0001780347 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,369 F2 · kind: Shares sold to cover tax witholding obligations associated with the vesting of restricted stock units. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 02:40 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 82 | $17.05 | $1,398.18 |
DisclosureSEC source: 0001209191-22-056887 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,534 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 82 shares by the Reporting Person on November 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 10, 2022 Filed May 13, 2022 01:23 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 1,454 | $13.57 | $19,724.96 |
DisclosureSEC source: 0001209191-22-028726 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,452 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,454 shares by the Reporting Person on May 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:53 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0001209191-22-002428 · doc4.xml · derivative · entry 2 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-01-05 F2 · derivative.exercise_date: 1/4th of the shares vest one year after January 6, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:53 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002428 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,998 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan. Read SEC document |
| November 10, 2021 Filed Nov 15, 2021 21:19 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 753 | $13.52 | $10,176.80 |
DisclosureSEC source: 0001209191-21-064449 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,998 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 753 shares by the Reporting Person on November 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 01, 2021 Filed Oct 2, 2021 00:00 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 961 | $19.26 | $18,505.02 |
DisclosureSEC source: 0001209191-21-058606 · doc4.xml · nonDerivative · entry 2 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,245 F2 · shares: Shares sold to cover tax withholding obligations associated with the vesting of the performance-based restricted stock unit award granted to the Reporting Person on March 9, 2021. Read SEC document |
| September 29, 2021 Filed Oct 2, 2021 00:00 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 8,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058606 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,206 F1 · shares: The shares became issuable upon the satisfaction of certain performance conditions that were established at the time of the Compensation Committee's approval of a performance-based restricted stock unit award on March 9, 2021. On September 29, 2021, the Compensation Committee certified the achievement of the performance criteria resulting in the vesting of 4,062 shares on September 29, 2021 and 4,063 shares on June 30, 2023. Read SEC document |
| May 10, 2021 Filed May 12, 2021 21:38 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 1,259 | $14.62 | $18,406.58 |
DisclosureSEC source: 0001209191-21-032154 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,081 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,259 shares by the Reporting Person on May 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 07, 2021 Filed Mar 9, 2021 00:48 UTC Amendment | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001209191-21-018772 · doc4a.xml · derivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-01-06 F1 · date: This Form 4 is being amended to correct the transaction date. F2 · derivative.exercise_date: 1/4th of the shares vest one year after January 7, 2021 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:14 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 822 | $15.27 | $12,548.65 |
DisclosureSEC source: 0001209191-20-058048 · doc4.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,822 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 822 shares by the Reporting Person on November 10, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 22:39 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $19.24 | $0.00 |
DisclosureSEC source: 0001209191-20-003342 · doc4.xml · derivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2030-01-09 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 10, 2020 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 07, 2020 Filed Jan 11, 2021 22:27 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001209191-21-003002 · doc4.xml · derivative · entry 1 Longpre Lara · CIK 0001780347 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-01-06 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 7, 2021 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| September 10, 2019 Filed Mar 18, 2024 21:40 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 965 | $10.64 | $10,267.60 |
DisclosureSEC source: 0001415889-24-008316 · form4-03182024_090300.xml · nonDerivative · entry 1 Longpre Lara · CIK 0001780347 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,372 F1 · price: The weighted average purchase price for the transaction reported was $10.64, and the range of prices were between $10.20 and $10.8799. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.